Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE SODIUM versus KAFOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTRIAXONE SODIUM versus KAFOCIN.
CEFTRIAXONE SODIUM vs KAFOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
KAFOCIN (cefepime/enmetazobactam) is a combination of a fourth-generation cephalosporin (cefepime) and a β-lactamase inhibitor (enmetazobactam). Enmetazobactam inhibits extended-spectrum β-lactamases (ESBLs) and other class A β-lactamases, restoring cefepime's activity against β-lactamase-producing bacteria. Cefepime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
1-2 g IV/IM every 12-24 hours; maximum 4 g/day.
1 g IV every 8 hours.
None Documented
None Documented
Terminal elimination half-life is 5.8-8.7 hours in adults with normal renal and hepatic function. In neonates, half-life is prolonged (up to 16 hours). In patients with renal impairment, half-life increases to 12-18 hours; in hepatic impairment, it may be 15-20 hours. Dose adjustment is not typically required unless both renal and hepatic impairment are present.
Terminal elimination half-life: 4.5-6.5 hours (increased to 12-18 hours in severe renal impairment; CrCl <30 mL/min).
Ceftriaxone is eliminated 33-67% unchanged in urine via glomerular filtration and tubular secretion, and the remainder is excreted in feces (primarily as microbiologically inactive metabolites) via biliary secretion. Biliary excretion accounts for approximately 35-45% of total clearance.
Renal: 60-80% unchanged; biliary/fecal: 15-30% as metabolites; total clearance ~120 mL/min.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic